JP2018518459A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018518459A5 JP2018518459A5 JP2017556587A JP2017556587A JP2018518459A5 JP 2018518459 A5 JP2018518459 A5 JP 2018518459A5 JP 2017556587 A JP2017556587 A JP 2017556587A JP 2017556587 A JP2017556587 A JP 2017556587A JP 2018518459 A5 JP2018518459 A5 JP 2018518459A5
- Authority
- JP
- Japan
- Prior art keywords
- molecule comprises
- immunomodulatory molecule
- ccl19
- optionally
- ccl21
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002519 immonomodulatory effect Effects 0.000 claims description 118
- 210000004027 cell Anatomy 0.000 claims description 67
- 102100036842 C-C motif chemokine 19 Human genes 0.000 claims description 60
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 claims description 60
- 102100036846 C-C motif chemokine 21 Human genes 0.000 claims description 59
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 claims description 59
- 102000013462 Interleukin-12 Human genes 0.000 claims description 58
- 108010065805 Interleukin-12 Proteins 0.000 claims description 58
- 102100023700 C-C motif chemokine 16 Human genes 0.000 claims description 57
- 101000978375 Homo sapiens C-C motif chemokine 16 Proteins 0.000 claims description 57
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 37
- 108010002350 Interleukin-2 Proteins 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 33
- 150000007523 nucleic acids Chemical group 0.000 claims description 26
- 108091033319 polynucleotide Proteins 0.000 claims description 22
- 102000040430 polynucleotide Human genes 0.000 claims description 22
- 239000002157 polynucleotide Substances 0.000 claims description 22
- 102000000588 Interleukin-2 Human genes 0.000 claims description 21
- 239000000427 antigen Substances 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 108010029697 CD40 Ligand Proteins 0.000 claims description 18
- 102100032937 CD40 ligand Human genes 0.000 claims description 18
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 18
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 18
- 102000003812 Interleukin-15 Human genes 0.000 claims description 18
- 108090000172 Interleukin-15 Proteins 0.000 claims description 18
- 108010042215 OX40 Ligand Proteins 0.000 claims description 18
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims description 18
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 claims description 17
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 claims description 17
- 102000039446 nucleic acids Human genes 0.000 claims description 17
- 108020004707 nucleic acids Proteins 0.000 claims description 17
- 239000013598 vector Substances 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 231100000053 low toxicity Toxicity 0.000 claims description 13
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 claims description 12
- 102000003810 Interleukin-18 Human genes 0.000 claims description 12
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims description 12
- 230000000295 complement effect Effects 0.000 claims description 10
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 8
- 230000002435 cytoreductive effect Effects 0.000 claims description 8
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 6
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 6
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 6
- 150000001413 amino acids Chemical group 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 6
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 6
- 238000001959 radiotherapy Methods 0.000 claims description 6
- 230000011664 signaling Effects 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 4
- 230000000139 costimulatory effect Effects 0.000 claims description 4
- 238000000315 cryotherapy Methods 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 238000011534 incubation Methods 0.000 claims description 4
- 210000000822 natural killer cell Anatomy 0.000 claims description 4
- 231100000331 toxic Toxicity 0.000 claims description 4
- 230000002588 toxic effect Effects 0.000 claims description 4
- 230000002463 transducing effect Effects 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 239000003550 marker Substances 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 2
- 241000282465 Canis Species 0.000 claims description 2
- 108091035707 Consensus sequence Proteins 0.000 claims description 2
- 241000283073 Equus caballus Species 0.000 claims description 2
- 241000282324 Felis Species 0.000 claims description 2
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 210000004102 animal cell Anatomy 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims description 2
- 238000004246 ligand exchange chromatography Methods 0.000 claims 30
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 230000008102 immune modulation Effects 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 230000001018 virulence Effects 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 102100030703 Interleukin-22 Human genes 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562155296P | 2015-04-30 | 2015-04-30 | |
| US62/155,296 | 2015-04-30 | ||
| PCT/US2016/030248 WO2016176639A1 (en) | 2015-04-30 | 2016-04-29 | Secretory tnt car cell immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018518459A JP2018518459A (ja) | 2018-07-12 |
| JP2018518459A5 true JP2018518459A5 (enExample) | 2019-04-18 |
Family
ID=57199395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556587A Pending JP2018518459A (ja) | 2015-04-30 | 2016-04-29 | 分泌性ｔｎｔ ｃａｒ細胞免疫療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20180291089A1 (enExample) |
| EP (1) | EP3288568A4 (enExample) |
| JP (1) | JP2018518459A (enExample) |
| CN (1) | CN107635569A (enExample) |
| AU (1) | AU2016255535A1 (enExample) |
| CA (1) | CA2984180A1 (enExample) |
| IL (1) | IL255280A0 (enExample) |
| WO (1) | WO2016176639A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI739740B (zh) * | 2015-04-22 | 2021-09-21 | 德商奎爾法克股份有限公司 | 用於治療腫瘤疾病之含有ｒｎａ的組成物 |
| US20220348633A1 (en) * | 2015-06-25 | 2022-11-03 | Icell Gene Therapeutics Llc | COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHOD OF USE THEREOF |
| US20200055917A1 (en) | 2016-09-27 | 2020-02-20 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules |
| AU2017342329A1 (en) * | 2016-10-11 | 2019-05-02 | Minerva Biotechnologies Corporation | Humanized anti-MUC1* antibodies and use of cleavage enzyme |
| KR20250072712A (ko) | 2016-12-02 | 2025-05-26 | 앤젤레스 테라퓨틱스, 인코포레이티드 | 합성 면역 수용체 및 이의 사용 방법 |
| EP3567049A4 (en) | 2016-12-28 | 2020-08-26 | Green Cross Lab Cell Corporation | CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME |
| US11851649B2 (en) * | 2017-05-17 | 2023-12-26 | Seattle Children's Hospital | Generating mammalian T cell activation inducible synthetic promoters (SYN+PRO) to improve T cell therapy |
| AU2018287317B2 (en) * | 2017-06-19 | 2024-06-20 | Medicenna Therapeutics Inc. | Uses and methods for IL-2 superagonists, agonists, and fusions thereof |
| RU2020114641A (ru) | 2017-09-26 | 2021-10-27 | Серо Терапьютикс, Инк. | Молекулы химерных интернализационных рецепторов и способы применения |
| CN111655732B (zh) | 2017-11-14 | 2023-09-12 | Gc细胞治疗 | 抗her2抗体或其抗原结合片段及包含其的嵌合抗原受体 |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| US20200352999A1 (en) * | 2017-11-22 | 2020-11-12 | La Jolla Institute For Allergy And Immunology | Use and production of engineered immune cells to disrupt nfat-ap1 pathway transcription factors |
| JP7290645B2 (ja) * | 2017-12-13 | 2023-06-13 | エックスディーシーエクスプローラー （シャンハイ） カンパニー リミテッド | ＥＧＦＲｖＩＩＩ抗体ならびにその複合体、製造方法および使用 |
| EP3774906A1 (en) | 2018-03-28 | 2021-02-17 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
| EP3774865A1 (en) | 2018-03-28 | 2021-02-17 | Cero Therapeutics, Inc. | Cellular immunotherapy compositions and uses thereof |
| CN108659133A (zh) * | 2018-04-26 | 2018-10-16 | 上海怡豪生物科技有限公司 | 肺癌的双靶点car-t治疗载体及其构建方法和应用 |
| CN108864289A (zh) * | 2018-04-26 | 2018-11-23 | 上海怡豪生物科技有限公司 | 胃癌的双靶点car-t治疗载体及其构建方法和应用 |
| CN108641000A (zh) * | 2018-04-26 | 2018-10-12 | 上海怡豪生物科技有限公司 | 肝癌的双靶点car-t治疗载体及其构建方法和应用 |
| CN108641001A (zh) * | 2018-04-26 | 2018-10-12 | 上海怡豪生物科技有限公司 | 结肠癌的双靶点car-t治疗载体及其构建方法和应用 |
| EP3822345B1 (en) * | 2018-05-15 | 2024-10-16 | CRAGE medical Co., Limited | Genetically engineered cell and application thereof |
| KR102653878B1 (ko) | 2018-08-01 | 2024-04-01 | 난트퀘스트, 인크. | 면역 요법의 안정한 유전적 변형을 위한 귀소 수용체 또는 사이토카인, 및 키메라 항원 수용체를 포함하는 4 시스트론 시스템 (a quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for genetic modification of immunotherapies) |
| US20210252069A1 (en) * | 2018-09-05 | 2021-08-19 | Seogkyoung KONG | Chimeric antigen receptor for solid cancer and t cells expressing chimeric antigen receptor |
| US20220096544A1 (en) * | 2018-09-20 | 2022-03-31 | Cafa Therapeutics Limited | Chemokine expressing cell and use thereof |
| EP3864142A4 (en) * | 2018-10-12 | 2023-07-19 | iCell Gene Therapeutics LLC | CHEMERA ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF |
| CN110818803B (zh) * | 2019-07-24 | 2023-01-03 | 浙江启新生物技术有限公司 | 分泌表达il15ra-il15融合蛋白、ccl21趋化因子的嵌合抗原受体-t细胞及应用 |
| WO2021057906A1 (zh) * | 2019-09-25 | 2021-04-01 | 科济生物医药（上海）有限公司 | 表达il-15的免疫效应细胞 |
| CN110684739B (zh) * | 2019-11-11 | 2022-05-27 | 深圳市体内生物医药科技有限公司 | 一种嵌合抗原受体t细胞及其应用 |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| US20220002718A1 (en) * | 2020-06-23 | 2022-01-06 | The General Hospital Corporation | Tunneling nanotube cells and methods of use thereof for delivery of biomolecules |
| CN112608902B (zh) * | 2020-12-21 | 2024-07-02 | 广东昭泰细胞生物科技有限公司 | 一种第四代car-t细胞及其应用 |
| WO2022220648A1 (ko) * | 2021-04-15 | 2022-10-20 | 주식회사 유틸렉스 | Hla-dr 특이적 키메라 항원 수용체 및 이의 용도 |
| CN115725504A (zh) * | 2021-08-26 | 2023-03-03 | 南京北恒生物科技有限公司 | 工程化免疫细胞及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9814383D0 (en) * | 1998-07-02 | 1998-09-02 | Cambridge Antibody Tech | Improvements relating to antibodies |
| CN1883454A (zh) * | 2006-06-01 | 2006-12-27 | 复旦大学 | 一种肿瘤坏死靶向单抗预定位脂质体给药系统及其应用 |
| CN101028525B (zh) * | 2006-09-01 | 2010-12-08 | 上海美恩生物技术有限公司 | 肿瘤细胞核单抗在物理治疗实体瘤中作为增效剂的用途 |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CN103304669A (zh) * | 2012-03-12 | 2013-09-18 | 复旦大学 | 人源化肿瘤免疫细胞因子tntil2及其制备方法和用途 |
| IL298125A (en) * | 2013-02-26 | 2023-01-01 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
-
2016
- 2016-04-29 JP JP2017556587A patent/JP2018518459A/ja active Pending
- 2016-04-29 CA CA2984180A patent/CA2984180A1/en not_active Abandoned
- 2016-04-29 WO PCT/US2016/030248 patent/WO2016176639A1/en not_active Ceased
- 2016-04-29 AU AU2016255535A patent/AU2016255535A1/en not_active Abandoned
- 2016-04-29 US US15/570,747 patent/US20180291089A1/en not_active Abandoned
- 2016-04-29 CN CN201680031760.6A patent/CN107635569A/zh active Pending
- 2016-04-29 EP EP16787271.2A patent/EP3288568A4/en not_active Withdrawn
-
2017
- 2017-10-26 IL IL255280A patent/IL255280A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018518459A5 (enExample) | ||
| JP7574243B2 (ja) | 抗ｃｄ７０キメラ抗原受容体 | |
| AU2016338747B2 (en) | Anti-CD30 chimeric antigen receptors | |
| JP7566628B2 (ja) | キメラ抗原受容体を発現する免疫細胞 | |
| KR102508182B1 (ko) | 형질전환 대식세포, 키메라 항원 수용체, 및 관련 방법 | |
| KR20190038567A (ko) | 키메라 항원 수용체 | |
| JP2013541335A5 (enExample) | ||
| JP2018531014A6 (ja) | 抗ｃｄ３０キメラ抗原受容体 | |
| KR20200131279A (ko) | 종양 특이적 t 세포 면역요법을 위한 il-13 수용체 알파 2 (il13ra2) 키메라 항원 수용체 | |
| JP2017537622A5 (enExample) | ||
| CN109265565B (zh) | 一种携带分子开关的抗CD79b嵌合抗原受体及其修饰的免疫细胞和应用 | |
| US11951131B2 (en) | Anti-SLAMF7 chimeric antigen receptors | |
| CN113056283A (zh) | 关于治疗血液肿瘤的工程化和非工程化γδ-T细胞的组合物和方法 | |
| CN107557337B (zh) | 一种抗ror1安全型嵌合抗原受体修饰的免疫细胞及其应用 | |
| CN103965362A (zh) | 一种可使t细胞趋向肿瘤部位的嵌合趋化因子受体 | |
| JP2014124186A (ja) | 多価抗体フラグメントおよびその三量体化複合体 | |
| JP2024501888A (ja) | Ｂｃｍａに特異的に結合する抗体およびその使用 | |
| CN115335407B (zh) | 结合cd19的嵌合抗原受体及其用途 | |
| CN107475275A (zh) | 嵌合抗原受体及其表达基因、双抗原调节的嵌合抗原受体修饰的t细胞及其应用 | |
| CN112996819A (zh) | 细胞分选系统及使用方法 | |
| CN102030822A (zh) | 人类新细胞因子VSTM1-v2及其应用 | |
| CN110981973B (zh) | 靶向人膜结合型和可溶性nkg2d配体的嵌合受体、核酸分子、免疫效应细胞及其应用 | |
| WO2018110374A1 (ja) | 殺細胞効果を有するキメラ抗原受容体遺伝子改変リンパ球 | |
| CN113785065A (zh) | T细胞受体及其使用方法 | |
| CN113853434A (zh) | T细胞受体及其使用方法 |